SEATTLE, WA, March 4, 2013 – Adaptive Biotechnologies Corporation, a leading provider of next-generation sequencing assays for the adaptive immune system, selected today four recipients to receive its Young Investigator Award for February. Winners will receive a $5,000 grant to use towards the purchase of immunoSEQ assays as part of their research in a variety of fields, such as immunology.
“I continue to be impressed by the quality of applications we receive for this award,” said Adaptive CEO Chad Robins. “These up-and-coming researchers show passion and brilliance for their work which bodes well for the future. I’m proud we’re able to support these dedicated, enthusiastic individuals.”
The winners of the Young Investigator Award are:
- Alan Watson, Ph.D., University of Pittsburgh
- Sven Malchow, Ph.D., University of Chicago, Dept. of Pathology
- Marta Pasikowska, King’s College London
- Michela Bardini, Centro Ricerca Tettamanti University of Milan Bicocca
The award is given four times a year to postdoctoral fellows and exceptional pre-doctoral students at qualifying universities researching any aspect of immunology. The next group of winners will be announced in May.
The recipients are selected by a panel of distinguished Ph.D. scientists working at Adaptive or consulting on the development of its immune profiling solution called immunoSEQ. All award applicants were asked to submit a proposal detailing their study. The criteria for selection was based on the innovative use of immunoSEQ assays in the research concept, the soundness of research design, and the value of the research to the field of immunology.
The Young Investigator Award is part of Adaptive’s ongoing support of outstanding researchers and its continuing effort to provide groundbreaking technology required to better understand, diagnose, and identify treatments for a variety of cancer, autoimmune disorders, and infectious diseases.
About Adaptive Biotechnologies Corporation and immunoSEQ™
Adaptive Biotechnologies Corporation, headquartered in Seattle, WA, is pioneering the field of genomic immunology. The company’s core competency is developing next generation sequencing assays that characterize the adaptive immune system, serving as a platform technology to the research community and the biopharmaceutical industry. Its flagship commercial product, immunoSEQ, uses a proprietary immune profiling assay to analyze T cells and B cells – critical components of the adaptive immune system’s defense against disease – with unprecedented depth and specificity. Sequencing the variable region of these immune cells allows researchers to characterize the complete immune repertoire of a patient or group of patients in search of immunologic biomarkers. Fueled by discoveries from immunoSEQ, the company is currently developing a pipeline of clinical assays that are specific to cancer diagnosis and prognosis. All of Adaptive Biotechnologies’ assays are coupled with a cloud-computing infrastructure that simplifies the interpretation of massive quantities of data in a user-friendly interface. immunoSEQ was launched in September 2010 and has a worldwide customer base.